000157171 001__ 157171
000157171 005__ 20240229123131.0
000157171 0247_ $$2doi$$a10.3390/cancers12071897
000157171 0247_ $$2pmid$$apmid:32674434
000157171 0247_ $$2altmetric$$aaltmetric:85845159
000157171 037__ $$aDKFZ-2020-01451
000157171 041__ $$aeng
000157171 082__ $$a610
000157171 1001_ $$0P:(DE-He78)958e8d5da8ac0ac935ef83acc9a50c37$$aFresnais, Margaux$$b0
000157171 245__ $$aRapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IM-MS/MS Assay.
000157171 260__ $$aBasel$$bMDPI$$c2020
000157171 3367_ $$2DRIVER$$aarticle
000157171 3367_ $$2DataCite$$aOutput Types/Journal article
000157171 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1597820656_17519
000157171 3367_ $$2BibTeX$$aARTICLE
000157171 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157171 3367_ $$00$$2EndNote$$aJournal Article
000157171 520__ $$aThe third-generation tyrosine kinase inhibitor (TKI), osimertinib, has revolutionized the treatment of patients with non-small cell lung carcinoma with epidermal growth factor receptor (EGFR)-activating mutation, and resistant to first- and second-generation TKIs. Osimertinib is now also proposed as a first-line therapy, thus extending the scope of applications in lung oncology. Personalized medicine approaches are still necessary to monitor if patients are exposed to adequate concentrations of osimertinib during their treatment. It would also help to understand the appearance of new resistances in patients after several months of dosing with osimertinib. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is currently the gold standard for the quantification of drugs in plasma enabling pharmacokinetic analyses and patient monitoring. In the present study, we propose an alternative to LC-MS/MS methods for the rapid and sensitive quantification of osimertinib in plasma using matrix-assisted laser desorption/ionization (MALDI) -MS. The presented assay requires only 3 min per sample for their preparation, analysis, and data extraction, and less than 3 h for quantification. A lower limit of quantification (LLOQ) of 5 ng/mL in plasma was retrieved. The method was fully validated, following the guidelines of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for bioanalytical method validation. The present developments prove the importance to consider alternative MS assays for time-efficient quantification of small molecule inhibitors in plasma in the context of personalized medicine for targeted therapies.
000157171 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000157171 588__ $$aDataset connected to CrossRef, PubMed,
000157171 7001_ $$aRoth, André$$b1
000157171 7001_ $$aFoerster, Kathrin I$$b2
000157171 7001_ $$aJäger, Dirk$$b3
000157171 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b4
000157171 7001_ $$00000-0003-0672-6876$$aHaefeli, Walter E$$b5
000157171 7001_ $$00000-0002-2190-1698$$aBurhenne, Jürgen$$b6
000157171 7001_ $$00000-0003-2003-1886$$aLonguespée, Rémi$$b7
000157171 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers12071897$$gVol. 12, no. 7, p. 1897 -$$n7$$pE1897$$tCancers$$v12$$x2072-6694$$y2020
000157171 909CO $$ooai:inrepo02.dkfz.de:157171$$pVDB
000157171 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)958e8d5da8ac0ac935ef83acc9a50c37$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000157171 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000157171 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000157171 9141_ $$y2020
000157171 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2018$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2019-12-21
000157171 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2018$$d2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2019-12-21
000157171 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2019-12-21
000157171 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x0
000157171 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000157171 980__ $$ajournal
000157171 980__ $$aVDB
000157171 980__ $$aI:(DE-He78)HD01-20160331
000157171 980__ $$aI:(DE-He78)B062-20160331
000157171 980__ $$aUNRESTRICTED